Metex

Methotrexate, the active ingredient in Metex, is an antimetabolite presented as an injection for subcutaneous use. It treats autoimmune diseases such as rheumatoid arthritis and psoriasis, and is also employed in oncology for certain leukemias and solid tumours.

GNH USA supplies Metex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used in the management of autoimmune and malignant conditions that involve rapid cell proliferation.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: improves skin lesions and reduces scaling. Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission. Other cancers (e.g., breast, lung): used as part of combination chemotherapy to enhance tumor control.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or malaise - Mouth sores (stomatitis) - Mild elevation of liver enzymes - Low blood cell counts (mild cytopenia) - Hair thinning or loss

Serious or Rare Side Effects: - Severe liver toxicity (hepatitis, fibrosis) - Pulmonary fibrosis or interstitial pneumonitis - Profound bone marrow suppression (pancytopenia) - Acute kidney injury or failure - Life‑threatening infections due to immunosuppression - Anaphylactic or severe hypersensitivity reactions

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

Monitor liver function: perform regular liver enzyme tests. Assess renal function: obtain baseline creatinine and periodic monitoring. Screen for infections: test for tuberculosis, hepatitis B/C before treatment. Avoid in pregnancy: drug is teratogenic and contraindicated (Category X). Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity and myelosuppression. - Penicillins (e.g., ampicillin): potentiate bone marrow suppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may increase hematologic toxicity. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.